Hydrogels comprising cell adhesive peptides and methods of use thereof
US-2024376438-A1 · Nov 14, 2024 · US
Peptides derived from NCAPG2 and their use
US9708378B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-9708378-B2 |
| Application number | US-201615285873-A |
| Country | US |
| Kind code | B2 |
| Filing date | Oct 5, 2016 |
| Priority date | Jan 15, 2014 |
| Publication date | Jul 18, 2017 |
| Grant date | Jul 18, 2017 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
NCAPG2, a component of condensin complex II, protein and novel peptides derived from the protein are provided. The peptide may include a fragment of the NCAPG2 protein. The peptide may be a peptide including a fragment of NCAPG2 protein having the amino acid sequence of SEQ ID NO: 7, wherein the fragment includes the amino acid residue number 805 or 1010 of SEQ ID NO: 7, a peptide having the sequence of SEQ ID NO: 8, or a peptide having the sequence of SEQ ID NO: 11. The protein or peptides can be used for preparing and screening pharmaceutical compositions for treating diseases or disorders associated with abnormal cell division including cancer.
First claim
Opening claim text (preview).
What is claimed is: 1. A method of treating a cancer in a subject in need thereof comprising administering a pharmaceutical composition comprising an effective amount of a peptide comprised of a fragment of the NCAPG2 protein as an active ingredient to the subject, wherein the peptide consists of the amino acid sequence of SEQ ID NOs: 8 or 11. 2. The method of claim 1 , wherein the peptide consisting of the amino acid sequence of SEQ ID NOs: 8 or 11 has phosphorylated threonine. 3. The method of claim 1 , wherein the peptide inhibits the normal mitosis of cancer cells by blocking the normal PLK1-Substrate binding by interacting with PLK1.
Assignees
Inventors
Classifications
from mammals · CPC title
- G01N33/5011Primary
for testing antineoplastic activity · CPC title
from mammals · CPC title
Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases · CPC title
transferring phosphorus containing groups, e.g. kinases (2.7) · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US9708378B2 cover?
- NCAPG2, a component of condensin complex II, protein and novel peptides derived from the protein are provided. The peptide may include a fragment of the NCAPG2 protein. The peptide may be a peptide including a fragment of NCAPG2 protein having the amino acid sequence of SEQ ID NO: 7, wherein the fragment includes the amino acid residue number 805 or 1010 of SEQ ID NO: 7, a peptide having the se…
- Who is the assignee on this patent?
- Nat Cancer Ct
- What technology area does this patent fall under?
- Primary CPC classification G01N33/5011. Mapped technology areas include Physics.
- When was this patent published?
- Publication date Tue Jul 18 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).